PT  - JOURNAL ARTICLE
AU  - Wijtvliet, Veerle P. W. M.
AU  - Ariën, Kevin K.
AU  - Abrams, Steven
AU  - Couttenye, Marie M.
AU  - Mestrez, Fabienne
AU  - Mariën, Joachim
AU  - De Winter, Benedicte Y.
AU  - Van Damme, Pierre
AU  - Pipeleers, Lissa
AU  - Wissing, Karl Martin
AU  - Abramowicz, Daniel
AU  - Ledeganck, Kristien J.
TI  - mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
AID  - 10.1101/2021.09.15.21263320
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.15.21263320
4099  - http://medrxiv.org/content/early/2021/11/16/2021.09.15.21263320.short
4100  - http://medrxiv.org/content/early/2021/11/16/2021.09.15.21263320.full
AB  - In this study of the humoral immune response after the SARS-CoV-2 mRNA vaccination, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients after first dose administration. While in DP the seroconversion rate levelled up to 92.8% after a second dose of SARS-CoV-2 mRNA vaccination, KTR stayed behind with a seroconversion rate of 62.4%. Futhermore, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean log-transformed antibody titer concentrations compared to BNT162b2 (Pfizer).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Antwerp University HospitalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for original and additional data should be directed to the corresponding author.